Replimune Announces Commercial Launch of TUDRIQEV for Advanced Melanoma
Replimune (REPL) has officially transitioned from a clinical-stage biotech to a commercial entity with the launch of its primary therapy, TUDRIQEV, targeting advanced melanoma. Early adoption metrics are strong, with over 15 medical centers prescribing the drug and 20 adding it to their formularies within the first 20 business days of availability. The company is leveraging an in-house manufacturing model to ensure supply chain stability, reporting more than a year of ready inventory and next-day delivery capabilities. Financially, Replimune maintains a solid liquidity position with $307.8 million in cash and cash equivalents, providing a runway of at least 12 months to support launch expenses and ongoing clinical studies.
Tickers: $REPL
Topics: Biotechnology Cash Reserves Commercial Launch Melanoma Treatment